MicroRNA 411 (MIR411)

MicroRNA 411 (MIR411) is a small non-coding RNA molecule belonging to the microRNA family, involved in the post-transcriptional regulation of gene expression. It binds to complementary sequences on messenger RNAs (mRNAs) and typically represses their translation or promotes degradation. MIR411 modulates key cellular processes such as proliferation, cell cycle progression, and apoptosis by targeting different effectors in various signaling pathways—including Hippo/YAP (regulating cardiomyocyte regeneration and survival after myocardial infarction), PI3K/AKT/mTOR (suppressing colorectal cancer progression), and SP1 (suppressing breast cancer progression)[1][2][4][6]. Expression changes in MIR411 are implicated in a range of diseases including cardiovascular disease (e.g., myocardial infarction and remodeling), various cancers (acting as either tumor suppressor or oncogene depending on the tissue), neurodegenerative disorders (such as Alzheimer’s disease), and inflammatory states[2][3][4][5][6]. Due to its diverse roles and regulation of critical signaling cascades, MIR411 is considered both a potential therapeutic target and a biomarker in disease contexts, with translational applications still in early preclinical stages.

Other names

hsa-mir-411MIRN411mir-411miRNA-411

Small non-coding RNA that downregulates specific mRNA targets, inhibiting their translation or inducing degradation Modulates cell signaling by targeting pathway effectors (e.g., PIK3R3 in colorectal cancer, SP1 in breast cancer, SPRY4 in lung cancer, FOXO1 in cardiomyocytes)[1][2][4][6]